ReShape Lifesciences CEO Gladney to resign | Personnel Moves – January 29, 2019

ReShape Lifesciences CEO Gladney

ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31.

Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said.

The company’s board of directors said they will immediately begin to look for a replacement, according to an SEC filing.

 AliveCor CEO Gundotra steps away

AliveCor CEO Vic Gundotra is stepping away from his position at the head of the company, according to a recent CNBC report.

Gundotra, a former senior VP with Google, said it will remain active on AliveCor’s board as the Mountain View, Calif.-based company searches for an internal replacement, according to the report.

“I’m leaving the company in a position of strength,” Gundotra said, according to CNBC.

“We all love Vic. We sold hundreds of thousands of devices and continue to gain more traction, so all I can say is he did a great job,” founder & chief medical officer David Albert said, according to the report.

AliveCor has not yet officially commented on the leadership change.

Read more

 Ahderium ousts CEO, CFO in major restructuring

New Zealand-based Adherium (ASK:ADR) has significantly downsized its workforce, including the exit of CEO Erik Anderson and CFO David Allinson, according to a New Zealand Herald report.

Former finance and business services VP Rob Turnbull will take up the position of GM and oversee the reorganization of the company, according to the report.

Alongside the exit of the execs, the company will also be slashing its general workforce by 80%, according to the NZ Herald.

“While the reduction in workforce is very regrettable, our focus remains to develop the company as has originally been planned. In meeting our customers’ commercial requirements, we will continue to develop leading solutions in our space, and in this our R&D activity will continue to be run from our Auckland office,” Turnbull told the Herald.

Turnbull said that the company would further explain its reorganization plans next month, according to the report.

Read more

 Functional Neuromodulation lifts COO Langevin to the corner office

Functional Neuromodulation said this week said that it tapped current prez & COO Todd Langevin to succeed existing CEO Vincent Owens, effective January 25.

Prior to joining Functional Neuromodulation, Langevin held senior leadership roles at Medtronic and CVRx, including acting as VP and GM of Medtronic’s DBS movement disorders business and as the company’s neuromodulation European business director.

“Todd has been instrumental in leading the company through the ADvance I study, CE Mark approval, and IDE approval of the ADvance II pivotal study of DBS-f.  FNM’s investors, employees and I have great confidence in Todd’s leadership and we look forward to beginning enrollment in ADvance II,” Owens said in a press release.

Read more

 AxoGen appointes Sandberg as CCO

AxoGen said last week that it appointed Eric Sandberg as its new chief commercial officer, replacing Jon Gingrich who is set to resign effective February 15.

Prior to his time with AxoGen, Sandberg held leadership roles at various medtech firms including Guidant, CardioDx, Tangent Medical and Boston Scientific, the Alachua, Fla.-based company said.

“We are excited to welcome Eric to our executive team; his breadth of commercialization experience and proven track record of execution will be invaluable as we introduce new applications and launch new products that expand and enhance our platform for nerve repair. Eric’s executive leadership will be instrumental as AxoGen continues to transform peripheral nerve repair and create a new standard of care,” prez & CEO Karen Zaderej said in a press release.

“AxoGen has an outstanding culture of innovation and excellence, and I look forward to building upon the company’s strong foundation. AxoGen has a tremendous opportunity to improve outcomes and quality of life for patients suffering the debilitating effects of peripheral nerve damage, across a growing range of applications. I am thrilled to join the Company at this critical and exciting time, as we pursue and develop these markets,” Sandberg said in a prepared statement.

Read more

The post ReShape Lifesciences CEO Gladney to resign | Personnel Moves – January 29, 2019 appeared first on MassDevice.

Adherium to expand in U.S. market with direct-to-consumer push for smart inhaler tech

  • Medical device startups: Here’s how you handle requirements

    Developing the product requirements is one of the most complex activities associated with product development, yet one of the most important.  Bill Betten, Betten Systems Solutions This is the third in a series of articles that discusses the design of innovative products in the highly regulated medical environment. The previous two articles focused on the […]

  • How does autonomous robotic surgery affect product liability?

    As more medical device manufacturers offer autonomous robotic surgery to their surgeon customers, traditional lines of legal defense most often taken by companies may change, according to experts from Nutter. David L. Ferrera and Melanie V. Woodward, Nutter Robots in surgery are not new. Indeed robots have been assisting surgeons for years, giving surgeons more […]

  • Medtech stories we missed this week: Jan. 26, 2018

    From Attune Medical receiving FDA 510(k) clearance to Synapse Medical having CE Mark approval, here are some medtech stories we missed this week but thought were still worth mentioning. 1. Attune Medical gets FDA 510(k) clearance Attune Medical announced in a Jan. 8 press releasethat it has received FDA 510(k) clearance for its EnsoETM model […]

  • The 5 biggest issues in patenting combo products

    Complexity and ownership issues make combination products a patenting labyrinth. Here are five key points to help you navigate the maze. David J. Dykeman and Roman Fayerberg, Greenberg Traurig The rise of personalized medicine has spurred another trend: the growth of combination products that blend biologics, drugs and medical devices to improve patient treatment. However, […]

  • FDA, FTC warn companies over deceptive opioid cessation products

    The FDA and the Federal Trade Commission have posted joint warning letters to companies that make and distribute opioid cessation products. The two watchdogs warned that the companies are illegally marketing their unapproved products as treatments or even cures for people with opioid addiction and withdrawal. Selling unapproved products as therapies for opioid addiction is […]

  • Why customer-centric marketing isn’t enough for medtech

    Customer-centric marketing has been a key pillar of marketing strategies across industries in recent years. But in medtech, the marketing ecosystem is a little more complicated. Rachel Mele, Vennli Customer-centricity has been a key pillar of marketing strategies across industries in recent years. In 2016, nine in 10 CMOs said their organizations were trying to become […]

  • How FDA’s digital health plan is shaking up its review process

    FDA is asking questions about how to overhaul digital health product regulation and relying on expertise within the industry to do so, according to Bakul Patel, FDA’s associate center director for digital health, who recently spoke with MDO. In late 2017, FDA launched the Digital Health Innovation Action Plan. Within that plan is a recipe […]

  • 3 secrets of medtech success from a true industry pioneer

    From stents to TAVR, Stanton Rowe has built a medtech legacy out of accomplishing the seemingly impossible. Here are three lessons from his career. Stanton Rowe has played a major role in two of the top medtech innovation success stories of recent decades: stents and transcatheter valve replacements. Listening to him speak at DeviceTalks West […]

  • Report: CMS nixes plans for pathway for expedited medical device coverage

    The Centers for Medicare & Medicaid Services has cancelled plans to create a new regulatory pathway that aimed to accelerate medicare coverage for medical devices, according to a ModernHealthcare report. The federal agency reportedly withdrew the proposition, known as Excite, from review at the White House’s Office of Management and Budget this month, nine months after […]

  • What should really trigger a CAPA?

    When should a problem with a medical device trigger a CAPA (Corrective Action and Preventative Action)? Jon Speer at Greenlight Guru has some thoughts.  Jon Speer, Greenlight Guru After years of working with medical device companies, we’ve found that there is a particular area that is often rife with issues for companies: CAPA (Corrective Action and Preventative Action). […]

  • 3M submits 510(k) for steam sterilization system

    3M has submitted an application to receive FDA 510(k) clearance for its Attest Super Rapid System for steam sterilization. The steam sterilization system can provide biological indicator results in 24 minutes. A faster readout time for steam will help improve patient safety while increasing workflow for sterilization professionals. “The focus of our sterilization science at […]